Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio-metabolic diseases that ...

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

Collaboration combines Novo Nordisk’s scientific leadership in obesity and cardiometabolic diseases with Septerna’s expertise in G protein-coupled receptor (GPCR) drug discovery Goal is to ...

Danish pharmaceutical giant Novo Nordisk and U.S. biotech Septerna agreed to collaborate on the development of pills to treat obesity, type 2 diabetes and other metabolic conditions. Under the ...

Septerna Inc. SEPN and Novo Nordisk A/S NVO announced an exclusive global collaboration and license agreement on Wednesday. The pact covers discovering, developing, and commercializing oral small ...

TD Cowen reiterated its Buy rating and $105.00 price target on Novo Nordisk (NYSE: NVO) Wednesday following meetings with the company’s senior leadership in Copenhagen. The pharmaceutical giant, with ...

Septerna's partnership with Novo Nordisk validates its GPCR drug discovery platform and injects $195 million in upfront cash, with potential for more than $2 billion in milestone payments.

You can reach Elaine on Signal at elaineywchen.70. Novo Nordisk said Wednesday that it will work with the biotech Septerna to develop oral GLP-1 obesity drugs, as it races to catch up to ...

Eli Lilly's Zepbound is the first and only approved dual GLP-1/GIP agonist, and Lilly is also working on its own triple ...

14 May 2025 – Septerna, Inc. (Nasdaq: SEPN) and Novo Nordisk today announced an exclusive global collaboration and license agreement to discover, develop and commercialise oral small molecule ...